Sumitomo Mitsui DS Asset Management Company Ltd Has $9.57 Million Position in Eli Lilly And Co (NYSE:LLY)

Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 27.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 72,840 shares of the company’s stock after acquiring an additional 15,903 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Eli Lilly And Co were worth $9,573,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of LLY. Voya Financial Advisors Inc. increased its stake in shares of Eli Lilly And Co by 14.4% during the third quarter. Voya Financial Advisors Inc. now owns 13,059 shares of the company’s stock worth $1,467,000 after acquiring an additional 1,640 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its position in shares of Eli Lilly And Co by 5.8% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,285 shares of the company’s stock worth $479,000 after acquiring an additional 233 shares in the last quarter. Norway Savings Bank increased its position in shares of Eli Lilly And Co by 8.7% in the third quarter. Norway Savings Bank now owns 6,912 shares of the company’s stock worth $773,000 after acquiring an additional 555 shares in the last quarter. Integrated Wealth Concepts LLC increased its position in shares of Eli Lilly And Co by 4.4% in the third quarter. Integrated Wealth Concepts LLC now owns 4,108 shares of the company’s stock worth $459,000 after acquiring an additional 174 shares in the last quarter. Finally, Windsor Group LTD increased its position in shares of Eli Lilly And Co by 2.0% in the fourth quarter. Windsor Group LTD now owns 65,802 shares of the company’s stock worth $8,648,000 after acquiring an additional 1,316 shares in the last quarter. Hedge funds and other institutional investors own 76.27% of the company’s stock.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 7,003 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $114.04, for a total transaction of $798,622.12. Following the transaction, the insider now directly owns 116,403,301 shares in the company, valued at approximately $13,274,632,446.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Myles O’neill sold 25,000 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the senior vice president now owns 40,424 shares in the company, valued at $4,850,880. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,780,504 shares of company stock valued at $219,697,912. Company insiders own 0.11% of the company’s stock.

LLY traded down $2.11 during trading hours on Friday, reaching $139.10. 1,797,240 shares of the stock traded hands, compared to its average volume of 2,971,564. The firm’s fifty day simple moving average is $131.31 and its two-hundred day simple moving average is $116.53. The company has a market cap of $135.92 billion, a price-to-earnings ratio of 16.92, a PEG ratio of 1.56 and a beta of 0.20. Eli Lilly And Co has a fifty-two week low of $101.36 and a fifty-two week high of $142.25. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.43 by $0.05. The business had revenue of $5.48 billion during the quarter, compared to analyst estimates of $5.50 billion. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The business’s revenue was up 3.2% on a year-over-year basis. During the same period last year, the business earned $1.39 EPS. On average, research analysts predict that Eli Lilly And Co will post 5.8 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 14th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a yield of 2.13%. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.65. The ex-dividend date of this dividend is Thursday, February 13th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.

Several equities research analysts have recently issued reports on LLY shares. UBS Group dropped their price objective on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research report on Thursday, October 17th. Morgan Stanley raised shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $116.00 to $150.00 in a research report on Wednesday, December 18th. They noted that the move was a valuation call. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly And Co from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Bank of America started coverage on shares of Eli Lilly And Co in a research report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price objective for the company. Finally, Argus increased their price objective on shares of Eli Lilly And Co from $145.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, December 30th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $135.67.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Balance Sheet

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.